A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...

Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.

In a report released yesterday, Tim Anderson from Bank of America Securities maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – ...

Eli Lilly (LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the production of key drug ingredients. Three of the four sites will produce ...

Eli Lilly plans four new U.S. manufacturing sites, expanding domestic production and reshoring pharmaceutical ingredient manufacturing. $50B expansion since 2020 includes four sites, creating over ...

For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...

At a time when the number of teens having babies in the Mountain State remains higher than the national average, maternal and child health researchers at West Virginia University found these infants ...

EXCLUSIVE: Blue Harbor Entertainment will release the Patricia Clarkson-starring drama Lilly, based on the true story of working-class hero Lilly Ledbetter, exclusively in theaters beginning May 9.